Connecting via Winsock to STN

Welcome to STN International!  Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * *  Welcome to STN International  * * * * * * * * * *

| | | |
|---|---|---|
| NEWS 1 | | Web Page for STN Seminar Schedule - N. America |
| NEWS 2 | JAN 02 | STN pricing information for 2008 now available |
| NEWS 3 | JAN 16 | CAS patent coverage enhanced to include exemplified prophetic substances |
| NEWS 4 | JAN 28 | USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats |
| NEWS 5 | JAN 28 | MARPAT searching enhanced |
| NEWS 6 | JAN 28 | USGENE now provides USPTO sequence data within 3 days of publication |
| NEWS 7 | JAN 28 | TOXCENTER enhanced with reloaded MEDLINE segment |
| NEWS 8 | JAN 28 | MEDLINE and LMEDLINE reloaded with enhancements |
| NEWS 9 | FEB 08 | STN Express, Version 8.3, now available |
| NEWS 10 | FEB 20 | PCI now available as a replacement to DPCI |
| NEWS 11 | FEB 25 | IFIREF reloaded with enhancements |
| NEWS 12 | FEB 25 | IMSPRODUCT reloaded with enhancements |
| NEWS 13 | FEB 29 | WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification |
| NEWS 14 | MAR 31 | IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats |
| NEWS 15 | MAR 31 | CAS REGISTRY enhanced with additional experimental spectra |
| NEWS 16 | MAR 31 | CA/CAplus and CASREACT patent number format for U.S. applications updated |
| NEWS 17 | MAR 31 | LPCI now available as a replacement to LDPCI |
| NEWS 18 | MAR 31 | EMBASE, EMBAL, and LEMBASE reloaded with enhancements |
| NEWS 19 | APR 04 | STN AnaVist, Version 1, to be discontinued |
| NEWS 20 | APR 15 | WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats |
| NEWS 21 | APR 28 | EMBASE Controlled Term thesaurus enhanced |
| NEWS 22 | APR 28 | IMSRESEARCH reloaded with enhancements |
| NEWS 23 | MAY 30 | INPAFAMDB now available on STN for patent family searching |
| NEWS 24 | MAY 30 | DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option |
| NEWS 25 | JUN 06 | EPFULL enhanced with 260,000 English abstracts |
| NEWS 26 | JUN 06 | KOREAPAT updated with 41,000 documents |
| NEWS 27 | JUN 13 | USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications |
| NEWS 28 | JUN 19 | CAS REGISTRY includes selected substances from web-based collections |
| NEWS 29 | JUN 25 | CA/CAplus and USPAT databases updated with IPC |

reclassification data
NEWS 30 JUN 30 AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 31 JUN 30 EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 32 JUN 30 STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 33 JUN 30 STN AnaVist enhanced with database content from EPFULL

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:52:03 ON 16 JUL 2008

=> file reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 08:52:27 ON 16 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 JUL 2008 HIGHEST RN 1034171-01-1
DICTIONARY FILE UPDATES: 15 JUL 2008 HIGHEST RN 1034171-01-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10541555\Struc 1.str





chain nodes :
10 11 18 19
ring nodes :
1 2 3 4 5 6 7 8 9 12 13 14 15 16
chain bonds :
6-10 10-11 16-18 18-19
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 12-13 12-16 13-14 14-15 15-16

exact/norm bonds :
2-7 3-9 6-10 7-8 8-9 10-11 12-13 12-16 13-14 14-15 15-16 16-18 18-19
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:Cb,Cy,Hy

10541555.trn

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> l1
SAMPLE SEARCH INITIATED 08:52:43 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 491 TO ITERATE

100.0% PROCESSED 491 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 8491 TO 11149
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> l1 full
FULL SEARCH INITIATED 08:52:46 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 9791 TO ITERATE

100.0% PROCESSED 9791 ITERATIONS 24 ANSWERS
SEARCH TIME: 00.00.01

L3 24 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 178.36 178.57

FILE 'CAPLUS' ENTERED AT 08:52:49 ON 16 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the

American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Jul 2008 VOL 149 ISS 3
FILE LAST UPDATED: 15 Jul 2008 (20080715/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> l3
L4 3 L3

=> d ibib abs hitstr 1-3

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:902349 CAPLUS
DOCUMENT NUMBER: 141:379802
TITLE: Preparation of indole derivatives as PPAR modulators for treatment of diabetes mellitus, syndrome X, and related disorders
INVENTOR(S): Conner, Scott Eugene; Knobelsdorg, James Allen; Mantlo, Nathan Bryan; Mayhugh, Daniel Ray; Wang, Xiaodong; Zhu, Guoxin; Schkeryantz, Jeffrey Michael; Michellys, Pierre-Yves
PATENT ASSIGNEE(S): Eli Lilly and Company, USA; Ligand Pharmaceuticals, Inc.
SOURCE: PCT Int. Appl., 262 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004092131 | A1 | 20041028 | WO 2003-US41698 | 20031231 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2003300131 | A1 | 20041104 | AU 2003-300131 | 20031231 |
| EP 1581491 | A1 | 20051005 | EP 2003-800390 | 20031231 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |

US 20060166983 A1 20060727 US 2005-541555 20051223
PRIORITY APPLN. INFO.: US 2003-438541P P 20030106
WO 2003-US41698 W 20031231
OTHER SOURCE(S): MARPAT 141:379802
GI




I




II

AB Title compds. I [wherein T1 = (un)substituted oxazol-4-yl, oxazol-5-yl, thiazol-4-yl, thiazol-5-yl, phenylene; R2 = hetero/alkyl; X = a bond, O, S, SO2, N; U = (un)substituted aliphatic linker wherein 1 C atom of the linker may be replaced with O, NH, or S; Y = C, O, S, NH, and a single bond; E = CR3R4A or A; A = alkylcarboxyl, alkylnitrile, alkylcarboxamide, (un)substituted alkylsulfonamide, alkylacylsulfonamide, alkyltetrazole; R3 = H, alkyl, alkoxy; R4 = H, aryloxy, (un)substituted alkyl, alkoxy, cycloalkyl, arylalkyl; R3CR4 = (un)substituted cycloalkyl; Z12 = -Z13-alkyl-Z14; Z13 = a single bond, CO, CO2, CONH and derivs., SO2; Z14 = (un)substituted hetero/aryl; R9 = H, alkyl, alkylenyl, halo, allyl, OH and derivs., (un)substituted arylalkyl, heteroaryl; R33 = alkyl, alkoxy, Ph, etc.; R = alkyl, carboxyalkyl, alkylsulfonaminocarbonylmethyl, etc; or stereoisomers, pharmaceutically acceptable salts, solvates, and hydrates thereof] were prepared as peroxisome proliferator activated receptor (PPAR) modulators. For example, reacting (5-Hydroxyindol-1-yl)acetic acid Et ester (preparation given) with 4-Chloromethyl-5-methyl-2-(4-trifluoromethylphenyl)oxazole, followed by saponification with NaOH gave II in near quant. yield. The binding and cotransfection efficacy for the compds. of the invention which are especially useful for modulating a PPAR receptor, are < 100 nM and > 50%, resp. I and their pharmaceutical compns. are expected to be effective in treating and preventing Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagulopathy, hypertension, atherosclerosis, and other disorders related to Syndrome X

and cardiovascular diseases.

IT 783350-83-4P, [5-[5-Methyl-2-(4-trifluoromethylphenyl)oxazol-4-ylmethoxy]indol-1-yl]acetic acid
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(PPAR modulator; preparation of indoles as PPAR modulators for treatment of diabetes mellitus, syndrome X, and other disorders)

RN 783350-83-4 CAPLUS

CN 1H-Indole-1-acetic acid, 5-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]- (CA INDEX NAME)




IT 783350-84-5P, [5-(5-Methyl-2-phenyloxazol-4-ylmethoxy)indol-1-yl]acetic acid 783350-85-6P, [5-[2-(4-Fluorophenyl)-5-methyloxazol-4-ylmethoxy]indol-1-yl]acetic acid 783350-86-7P, [5-[[2-(4-Benzyloxyphenyl)-5-methyloxazol-4-yl]methoxy]indol-1-yl]acetic acid 783350-91-4P, [5-[4-Methyl-2-(4-trifluoromethylphenyl)oxazol-5-ylmethoxy]indol-1-yl]acetic acid 783350-92-5P, 2-Methyl-2-[5-[4-methyl-2-(4-trifluoromethylphenyl)oxazol-5-ylmethoxy]indol-1-yl]propionic acid 783350-93-6P, 2-[5-[4-Methyl-2-(4-trifluoromethylphenyl)oxazol-5-ylmethoxy]indol-1-yl]propionic acid 783351-08-6P, 5-[5-[5-Methyl-2-(4-trifluoromethylphenyl)oxazol-4-ylmethoxy]indol-1-yl]pentanoic acid 783351-09-7P, 5-[5-[2-(4-Bromophenyl)-5-methyloxazol-4-ylmethoxy]indol-1-yl]pentanoic acid 783351-12-2P, 3-[5-[2-(4-Bromophenyl)-5-methyloxazol-4-ylmethoxy]indol-1-yl]propionic acid 783351-17-7P, [5-[4-Ethyl-2-(4-trifluoromethylphenyl)oxazol-5-ylmethoxy]indol-1-yl]acetic acid 783351-64-4P, [5-[1-[4-Ethyl-2-(4-trifluoromethylphenyl)oxazol-5-yl]ethoxy]indol-1-yl]acetic acid 783351-73-5P, 2-Methyl-2-[5-(5-methyl-2-phenyloxazol-4-ylmethoxy)indol-1-yl]propionic acid 783351-74-6P, 2-[5-[2-(4-Trifluoromethylphenyl)-5-methyloxazol-4-ylmethoxy]indol-1-yl]-2-methylpropionic acid 783351-75-7P, 2-[5-[2-(4-Fluorophenyl)-5-methyloxazol-4-ylmethoxy]indol-1-yl]-2-methylpropionic acid 783351-76-8P, 2-[5-[2-(4-Bromophenyl)-5-methyloxazol-4-ylmethoxy]indol-1-yl]-2-methylpropionic acid 783352-18-1P, N-[2-[5-[5-Methyl-2-(4-trifluoromethylphenyl)oxazol-4-ylmethoxy]indol-1-yl]acetyl]methanesulfonamide 783352-20-5P, N-[2-[5-[5-Methyl-2-(4-trifluoromethylphenyl)oxazol-4-ylmethoxy]indol-1-yl]acetyl]benzenesulfonamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(PPAR modulator; preparation of indoles as PPAR modulators for treatment of diabetes mellitus, syndrome X, and other disorders)

RN 783350-84-5 CAPLUS

CN 1H-Indole-1-acetic acid, 5-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]- (CA

INDEX NAME)



RN 783350-85-6 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]- (CA INDEX NAME)



RN 783350-86-7 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[[5-methyl-2-[4-(phenylmethoxy)phenyl]-4-oxazolyl]methoxy]- (CA INDEX NAME)



RN 783350-91-4 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-oxazolyl]methoxy]- (CA INDEX NAME)



RN 783350-92-5 CAPLUS
CN 1H-Indole-1-acetic acid, α,α-dimethyl-5-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-oxazolyl]methoxy]- (CA INDEX NAME)



RN 783350-93-6 CAPLUS
CN 1H-Indole-1-acetic acid, α-methyl-5-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-oxazolyl]methoxy]- (CA INDEX NAME)



RN 783351-08-6 CAPLUS
CN 1H-Indole-1-pentanoic acid, 5-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]- (CA INDEX NAME)



RN 783351-09-7 CAPLUS
CN 1H-Indole-1-pentanoic acid, 5-[[2-(4-bromophenyl)-5-methyl-4-oxazolyl]methoxy]- (CA INDEX NAME)



RN 783351-12-2 CAPLUS
CN 1H-Indole-1-propanoic acid, 5-[[2-(4-bromophenyl)-5-methyl-4-

oxazolyl]methoxy]-  (CA INDEX NAME)



RN  783351-17-7  CAPLUS
CN  1H-Indole-1-acetic acid, 5-[[4-ethyl-2-[4-(trifluoromethyl)phenyl]-5-oxazolyl]methoxy]-  (CA INDEX NAME)



RN  783351-64-4  CAPLUS
CN  1H-Indole-1-acetic acid, 5-[1-[4-ethyl-2-[4-(trifluoromethyl)phenyl]-5-oxazolyl]ethoxy]-  (CA INDEX NAME)



RN  783351-73-5  CAPLUS
CN  1H-Indole-1-acetic acid, α,α-dimethyl-5-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]-  (CA INDEX NAME)



RN  783351-74-6  CAPLUS
CN  1H-Indole-1-acetic acid, α,α-dimethyl-5-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]-  (CA INDEX NAME)



RN 783351-75-7 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]-α,α-dimethyl- (CA INDEX NAME)



RN 783351-76-8 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[[2-(4-bromophenyl)-5-methyl-4-oxazolyl]methoxy]-α,α-dimethyl- (CA INDEX NAME)



RN 783352-18-1 CAPLUS
CN 1H-Indole-1-acetamide, N-(methylsulfonyl)-5-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]- (CA INDEX NAME)



RN 783352-20-5 CAPLUS
CN 1H-Indole-1-acetamide, 5-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]-N-(phenylsulfonyl)- (CA INDEX NAME)



IT 783352-25-0P, [5-[5-Methyl-2-(4-trifluoromethylphenyl)oxazol-4-ylmethoxy]indol-1-yl]acetic acid ethyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of indoles as PPAR modulators for treatment of diabetes mellitus, syndrome X, and other disorders)
RN 783352-25-0 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:570981 CAPLUS
DOCUMENT NUMBER: 139:133571
TITLE: Preparation of heterocyclic compounds such as oxazoles as anticancer agents
INVENTOR(S): Tasaka, Akihiro; Taniguchi, Takahiko; Takakura,

Nobuyuki; Momose, Yu; Naito, Kenichiro; Tsujimoto, Saori
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 274 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2003059907 | A1 | 20030724 | WO 2003-JP310 | 20030116 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2003203170 | A1 | 20030730 | AU 2003-203170 | 20030116 |
| JP 2003277379 | A | 20031002 | JP 2003-8814 | 20030116 |

PRIORITY APPLN. INFO.: JP 2002-9255 A 20020117
WO 2003-JP310 W 20030116

OTHER SOURCE(S): MARPAT 139:133571
GI




I

AB The title compds. I [A is a nitrogenous heterocycle; B is an optionally substituted aromatic homocycle or an optionally substituted aromatic heterocycle; C is a 5- or 6-membered nitrogenous heterocycle which may be substituted; R is an optionally substituted aromatic homocyclic group or the like; m is an integer of 0 to 2; n is an integer of 1 to 5; X is oxygen or the like; and Y and Z may be the same or different from each other and are each a single bond, an oxygen atom, an optionally substituted carbon atom, or the like] are prepared Compds. of this invention in vitro showed IC50 values of < 0.05 μM to 0.2 μM against the growth of breast cancer cells BT-474. Formulations containing I are given.

IT 568595-48-2P 568595-51-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. such as oxazole derivs. as anticancer agents)

RN 568595-48-2 CAPLUS

CN 1H-Imidazole-2-methanol, 1-[3-[5-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]-1H-indol-1-yl]propyl]-

(CA INDEX NAME)

Double bond geometry as shown.



RN 568595-51-7 CAPLUS
CN 1H-Indole, 1-[3-(1H-1,2,3-triazol-1-yl)propyl]-5-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:661173 CAPLUS
DOCUMENT NUMBER: 124:8801
ORIGINAL REFERENCE NO.: 124:1861a,1864a
TITLE: Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazolealkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
INVENTOR(S): Musser, John H.; Kreft, Anthony F., III; Failli, Amedeo A.; Demerson, Christopher A.; Shah, Uresh S.; Nelson, James A.
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: U.S., 35 pp. Cont.-in-part of U.S. 5,229,516. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 5420289 | A | 19950530 | US 1993-29199 | 19930310 |
| CA 2090042 | A1 | 19910428 | CA 1990-2090042 | 19901027 |
| US 5229516 | A | 19930720 | US 1992-911434 | 19920710 |

PRIORITY APPLN. INFO.: US 1989-428260 B2 19891027
US 1990-596134 B2 19901011
US 1992-911434 A2 19920710
CA 1990-2070422 A3 19901027
OTHER SOURCE(S): CASREACT 124:8801; MARPAT 124:8801
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB This invention relates to substituted indole derivs. A(CH2)nOB wherein A = I or II wherein R1 is hydrogen, lower alkyl, Ph or Ph substituted with trifluoromethyl; R2 is hydrogen or lower alkyl; or R1 and R2 taken together form a benzene ring; R3 is hydrogen or lower alkyl; n is 1-2; B is III-VII wherein R4 is, e.g., CO2R2, m is 0-3; R5 is A(CH2)nOC6H4 or Ph or Ph substituted by halo, lower alkylthio, lower alkylsulfinyl or lower alkylsulfonyl; R6 is A(CH2)nO or halo; R7 is lower alkyl; Y is CH2 or O; R8 is lower alkyl or (CH2)mCO2R3 ; R9 is COR10 or (CH2)oR10, o is 1-4; R10 is lower alkyl, Ph, Ph substituted with carboxy, halo, lower alkyl, loweralkylthio or loweralkylsulfinyl; naphthyl, pyridyl, furanyl, quinolinyl, or 2-R14-thiazolyl; R11 is lower alkyl or phenyl; R12 is hydrogen or loweralkylcarbonyl R13 is hydrogen, hydroxy, lower alkyl or lower alkoxy; R14 is Ph or halophenyl; Z2 is hydrogen, lower alkyl or N(CH3)OH; and the pharmacol. acceptable salts thereof possessing lipoxygenase inhibitory, phospholipase A2 inhibitory and leukotriene antagonist activity, which are useful as anti-inflammatory, antiallergic and cytoprotective agents. Thus, e.g., condensation of 2-methyl-5-(2-quinolinylmethoxy)indene-3-acetic acid Et ester (preparation given, mixture of endo and exo isomers) with p-chlorobenzaldehyde afforded 3-[(4-chlorophenyl)methylene]-2-methyl-6-(2-quinolinylmethoxy)-3H-indene-1-acetic acid [VIII, Q = 2-quinolinylmethyl, mixture of Z (major) and E (minor) isomers]. The specificity of action of PLA2 inhibitors can be determined by the activity of test compds. to inhibit the synthesis of LTB4 by rat glycogen-elicited polymorphonuclear leukocytes (PMN) in the presence of exogenous substrate: VIII demonstrated 96% inhibition at 10 mM. VIII also inhibited the synthesis of the arachidonic acid cyclooxygenase oxidation product PGE2 with 81% inhibition at 10 mM. VIII inhibited the release of arachidonic acid from an arachidonic acid-containing substrate by the action of phospholipase A2 enzyme from human synovial fluid with IC50 = 9.7 mM. Further assays demonstrated that the compds. of the invention exerted an inhibitory effect on both the lipoxygenase pathway and the cyclooxygenase pathway and have significant leukotriene (LTD4) antagonist activity. The compds. of the invention inhibited the acute inflammatory response and inhibited 5-lipoxygenase in human whole blood.

IT 170563-10-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(substituted indole-, indene-, pyranoindole- and tetrahydrocarbazolealkanoic acid derivs. as inhibitors of PLA2 and lipoxygenase)

RN 170563-10-7 CAPLUS

CN 1H-Indole-3-acetic acid, 2-methyl-1-(phenylmethyl)-5-[(2-phenyl-4-oxazolyl)methoxy]-, ethyl ester (CA INDEX NAME)



IT 170563-11-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(substituted indole-, indene-, pyranoindole- and tetrahydrocarbazolealkanoic acid derivs. as inhibitors of PLA2 and lipoxygenase)
RN 170563-11-8 CAPLUS
CN 1H-Indole-3-acetic acid, 2-methyl-1-(phenylmethyl)-5-[(2-phenyl-4-oxazolyl)methoxy]- (CA INDEX NAME)



IT 170563-09-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(substituted indole-, indene-, pyranoindole- and tetrahydrocarbazolealkanoic acid derivs. as inhibitors of PLA2 and lipoxygenase)
RN 170563-09-4 CAPLUS
CN 1H-Indole-3-acetic acid, 2-methyl-5-[(2-phenyl-4-oxazolyl)methoxy]-, ethyl ester (CA INDEX NAME)



=> log h

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 16.83 | 195.40 |

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| CA SUBSCRIBER PRICE | -2.40 | -2.40 |

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 08:53:12 ON 16 JUL 2008